EIF4EBP1 and breast carcinoma: Given the relationship between expression of 4EBP1 in the 8p11-p12 amplicon and hyperactivation of mTORC1 observed in endocrine resistant breast cancers, PI3K/AKT/mTORC1 targeted therapies have been suggested for 4EBP1 expressing breast cancers [46, 77–81].